Project Grant R43GM152994

Award Date 1/1/24
Completion Date 12/31/24
Dollars Obligated $545K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $350,000.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop an artificial intelligence-based platform for optimizing peptide-based drug candidates. The key products or services to be delivered include: Methods for encoding non-canonical amino acids and cyclic peptides to enable high-performance machine learning on commercial peptide sequence, activity, stability, and...
This Project Grant award of $306,872.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), aims to develop a new 3D shape matching methodology that accounts for water molecules when comparing ligands during drug discovery. The key products and services to be delivered include: Adapting an existing algorithm (WATGEN) to predict water positions in unbound proteins and protein-ligand complexes, and calculate...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $124,767 to The Regents of the University of California, San Francisco (UCSF) to develop and test a pipeline for the de novo design of protein "enfolds" that can conditionally release cell-penetrating peptides (CPPs) and antimicrobial peptides (AMPs). The goal is to enhance the tissue specificity and stability of...
This $400,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) will fund research to develop an integrated computational framework for predicting and designing "photoenzymes" - enzymes that can utilize light to catalyze non-natural chemical reactions important for pharmaceutical synthesis. The key products or services to be delivered include: 1) Machine learning-enhanced...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $202,274 to develop an easy-to-use computer program for predicting the structure and degrading efficiency of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional molecules that induce the degradation of target proteins by recruiting them to E3 ubiquitin ligases. The awarded project aims to implement a...
This Project Grant award from the National Science Foundation's Division of Chemistry under the Mathematical and Physical Sciences (CFDA 47.049) program supports a collaborative research effort led by Emory University and the University of Illinois Chicago to design and develop peptide-based filamentous nanomaterials. The $300,000 award, effective from August 1, 2024 to July 31, 2027, will leverage computational methods to systematically explore the energetics and structural designability of...
Quantum Simulation Technologies Inc., doing business as Qsimulate, received a $442,362 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop and validate a novel high-performance implementation of density functional theory quantum mechanics for scoring ligand-protein interactions. The award was made under the Biomedical Research and Research Training program (CFDA 93.859), which supports basic research that increases understanding of...
This Project Grant award of $275,956 from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program aims to develop an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimization of their dosing. The key products and services to be delivered under this award include: 1) Adoption of 3D bioprinting to generate vascularized ductal...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $314,363 to Delineate Inc. to develop an innovative platform that uses large language models (LLMs) to accelerate the building and repurposing of quantitative systems pharmacology (QSP) models from scientific literature. The key objectives are to: (1) develop an LLM-powered platform for efficient QSP model construction...
This $280,000 Project Grant award from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program supports the development of comprehensive generative AI methodologies and computational tools to expedite drug discovery, enhance cost efficiency, and improve success rates. The project aims to create a holistic generative AI framework capable of generating high-quality drug candidates with multiple desired properties, with the potential to transform...

BINDING FREE ENERGY PREDICTIONS FOR PEPTIDE DRUGS: A NOVEL MACHINE LEARNING-BASED PEPTIDE SIMULATION MODEL FOR HIGH-THROUGHPUT COMPUTATIONAL LEAD OPTIMIZATION WITH QUANTUM MECHANICAL ACCURACY. - PROJECT SUMMARY/ABSTRACT NEARLY ALL MODERN DRUG DISCOVERY EFFORTS BEGIN WITH A VIRTUAL SCREENING CAMPAIGN, AND THERE ARE NOW SEVERAL DRUGS AVAILABLE ON THE MARKET THAT WERE ORIGINALLY IDENTIFIED THROUGH COMPUTATIONAL EFFORTS. SMALL MOLECULE DRUG DISCOVERY, IN PARTICULAR, HAS BENEFITED FROM THE INTEGRATION OF COMPUTATIONAL CHEMISTRY TOOLS THAT HAVE BECOME CAPABLE OF THE NECESSARY THROUGHPUT DUE TO ADVANCES IN COMPUTATIONAL POWER AND ALGORITHMIC DEVELOPMENT. BINDING FREE ENERGY CALCULATIONS HAVE ENHANCED THE PRACTICE OF SMALL MOLECULE LEAD OPTIMIZATION AND HAVE HELPED EXPEDITE THE DEVELOPMENT OF EFFECTIVE DRUGS TO TRANSFORM THE HEALTHCARE LANDSCAPE. PEPTIDE DRUGS ARE WIDELY CONSIDERED TO BE A PROMISING, YET CURRENTLY UNDERUTILIZED, CLASS OF DRUGS DUE TO THEIR HIGH LEVEL OF TUNABILITY WITH MODERN SYNTHESIS METHODS. THEIR LARGE EXPOSED SURFACE AREA RELATIVE TO SMALL MOLECULE DRUGS SUPPORTS AN INCREASED LEVEL OF SPECIFICITY AND THE ROUGHLY 80 PEPTIDE DRUGS CURRENTLY AVAILABLE ON THE MARKET REPRESENT SOME OF THE HIGHEST THERAPEUTIC INDICES OF KNOWN DRUGS. PEPTIDE DRUGS EVEN OFFER THE OPPORTUNITY TO ADDRESS TARGETS THAT WERE PREVIOUSLY THOUGHT TO BE UNDRUGGABLE. PEPTIDE DRUGS ARE SITUATED TO SIMILARLY BENEFIT FROM COMPUTATIONAL LEAD OPTIMIZATION STRATEGIES, BUT THE APPLICATION OF EXISTING TOOLS FOR ACCELERATING DISCOVERY EFFORTS IS LESS ESTABLISHED THAN FOR SMALL MOLECULE DRUGS. THE BARRIER FOR ACHIEVING WIDESPREAD SUCCESS IN COMPUTATIONAL PEPTIDE LEAD OPTIMIZATION IS TWO-FOLD: THE INCREASED SIZE OF PEPTIDE DRUGS MAKES THE NECESSARY CONFORMATIONAL SAMPLING MORE CHALLENGING, AND THE DIVERSITY IN CHEMICAL CHARACTER AMONG DIFFERENT PEPTIDE DRUGS MAKES IT DIFFICULT TO FIT A RELIABLE CLASSICAL SIMULATION MODEL. THE FORMER CHALLENGE CAN BE OVERCOME THROUGH EFFICIENT CONFORMATIONAL SAMPLING APPROACHES, WHILE THE LATTER CAN BE ADDRESSED BY QUANTUM MECHANICAL CALCULATIONS THAT AVOID THE NEED FOR A RESTRICTIVE FIT TO ANALYTICAL MODELS. OVERCOMING BOTH OF THESE CHALLENGES SIMULTANEOUSLY REQUIRES AN INNOVATIVE APPROACH, BECAUSE THE SOLUTIONS TO EACH OF THEM INDEPENDENTLY HAVE BEEN, UNTIL RECENTLY, MUTUALLY EXCLUSIVE. THE OBJECTIVE OF THE PROPOSED RESEARCH IS TO MAKE COMPUTATIONAL LEAD OPTIMIZATION RELIABLE FOR PEPTIDE DRUG DISCOVERY BY DEVELOPING A MACHINE LEARNING-BASED PEPTIDE SIMULATION MODEL THAT SIMULTANEOUSLY OVERCOMES BOTH OF THE AFOREMENTIONED CHALLENGES. WE WILL ACHIEVE THIS BY TRAINING A MACHINE LEARNING POTENTIAL ON THE BASIS OF QUANTUM MECHANICAL SIMULATION DATA, WHICH WILL BE IMPLEMENTED ON OUR QSP LIFE MOLECULAR SIMULATION PLATFORM FOR EFFICIENTLY CALCULATING PEPTIDE BINDING FREE ENERGIES.

Posted 12/15/23, 12:00 AM